These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 22046084)

  • 21. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
    Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
    Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg).
    Nyssen OP; Vaira D; Pérez Aísa Á; Rodrigo L; Castro-Fernandez M; Jonaitis L; Tepes B; Vologzhanina L; Caldas M; Lanas A; Lucendo AJ; Bujanda L; Ortuño J; Barrio J; Huguet JM; Voynovan I; Lasala JP; Sarsenbaeva AS; Fernandez-Salazar L; Molina-Infante J; Jurecic NB; Areia M; Gasbarrini A; Kupčinskas J; Bordin D; Marcos-Pinto R; Lerang F; Leja M; Buzas GM; Niv Y; Rokkas T; Phull P; Smith S; Shvets O; Venerito M; Milivojevic V; Simsek I; Lamy V; Bytzer P; Boyanova L; Kunovský L; Beglinger C; Doulberis M; Marlicz W; Goldis A; Tonkić A; Capelle L; Puig I; Megraud F; Morain CO; Gisbert JP;
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2243-2257. PubMed ID: 34954341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.
    Treiber G; Ammon S; Malfertheiner P; Klotz U
    Helicobacter; 2002 Aug; 7(4):225-31. PubMed ID: 12165029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing the MIC breakpoints of amoxicillin and tetracycline for antibiotic selection in the rescue therapy of H. pylori with bismuth quadruple regimen.
    Hsieh MT; Chang WL; Wu CT; Yang HB; Kuo HY; Lin MY; Cheng HC; Tsai YC; Sheu BS
    Eur J Clin Pharmacol; 2020 Nov; 76(11):1581-1589. PubMed ID: 32591943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
    Zhou Y; Ye Z; Wang Y; Zhang Y; Tang Z; Yan W; Jiang Y; Huang Y
    Helicobacter; 2020 Apr; 25(2):e12679. PubMed ID: 31958193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
    Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
    Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
    Altintaş E; Ulu O; Sezgin O; Aydin O; Camdeviren H
    Turk J Gastroenterol; 2004 Jun; 15(2):90-3. PubMed ID: 15334317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.
    Fallone CA; Moss SF; Malfertheiner P
    Gastroenterology; 2019 Jul; 157(1):44-53. PubMed ID: 30998990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
    Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
    BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
    Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
    Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.
    Gisbert JP; Castro-Fernández M; Bermejo F; Pérez-Aisa A; Ducons J; Fernández-Bermejo M; Bory F; Cosme A; Benito LM; López-Rivas L; Lamas E; Pabón M; Olivares D;
    Am J Gastroenterol; 2006 Feb; 101(2):243-7. PubMed ID: 16454825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
    Li Y; Huang X; Yao L; Shi R; Zhang G
    Wien Klin Wochenschr; 2010 Jul; 122(13-14):413-22. PubMed ID: 20628905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
    Chey WD; Leontiadis GI; Howden CW; Moss SF
    Am J Gastroenterol; 2017 Feb; 112(2):212-239. PubMed ID: 28071659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line Therapy for Helicobacter Pylori Eradication: State of the Art.
    Losurdo G; D'Abramo FS; Piazzolla M; Rima R; Continisio A; Pricci M; Ierardi E; Di Leo A
    Mini Rev Med Chem; 2022; 22(19):2430-2437. PubMed ID: 35339174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on the second-line treatment of
    Shih CA; Shie CB; Tai WC; Chuah SK; Lee HC; Hsu PI
    Therap Adv Gastroenterol; 2023; 16():17562848231192750. PubMed ID: 37675247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis.
    Han Z; Li Y; Kong Q; Liu J; Wang J; Wan M; Lin M; Lin B; Zhang W; Ding Y; Wang S; Mu Y; Duan M; Zuo X; Li YQ
    Helicobacter; 2022 Dec; 27(6):e12930. PubMed ID: 36156332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Helicobacter pylori eradication following first-line treatment failure in Europe: What, how and when chose among different standard regimens? A systematic review.
    De Francesco V; Zullo A; Manta R; Gatta L; Fiorini G; Saracino IM; Vaira D
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e66-e70. PubMed ID: 33741798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.